- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02099994
Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults (HIV-CORE 004)
A Phase I/IIa Clinical Trial of HIV-1 Vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and Ad35-GRIN in Combined Regimens in Healthy HIV-1/2-negative Adults in Nairobi.
Study Overview
Status
Conditions
Detailed Description
The main objectives of this study are to determine the vaccines' safety and immunogenicity in an African population, and further strengthen the vaccine trial capacity in the South.
HIV-CORE 004 is a double blind, placebo controlled randomized Phase I/IIa study designed to evaluate the safety and immunogenicity of different delivery regimens using three novel HIV-1 vaccines pSG2.HIVconsv DNA (D) with and without electroporation (e), adenovirus Ad35-GRIN (A) and poxvirus MVA.HIVconsv (M) administered by intramuscular needle injection in heterologous prime-boost regimens.
72 healthy, low-risk, HIV-1-uninfected adult volunteers in Nairobi will be randomly assigned to one of three groups, AM, DDDAM and DeDeDeAM each containing 20 vaccinees and 4 placebo recipients.
Firstly, this study aims to evaluate the safety and tolerability of the vaccines pSG2.HIVconsv DNA (D) with and without electroporation (e), adenovirus Ad35-GRIN (A) and poxvirus MVA.HIVconsv (M).
Secondly, we shall determine the effect of electroporation during DNA priming on the frequency, durability and/or quality of T cell responses (DDDAM vs DeDeDeAM).
Thirdly, we shall determine whether priming with three DNA vaccinations with or without electroporation affects the frequency, durability and/or quality of T cell responses to the HIVconsv immunogen compared to that seen in the AM regimen (AM vs DDDAM/DeDeDeAM).
As this is the first study of the combined HIVconsv vaccines in an African population, of the pSG2.HIVconsv DNA with electroporation, and the combination of the two HIVconsv vaccines with Ad35-GRIN, this trial has been designed as a pilot study to compare different vector combinations. The sample sizes will only allow detection of large response differences between volunteers in the three groups, thus, yielding data that are primarily descriptive.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Nairobi, Kenya
- KAVI-Kangemi clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adults aged 18-50
- Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
- Written informed consent.
- Willing to undergo HIV-1 testing, counselling and receive test results.
- All female volunteers must be willing to undergo urine pregnancy tests
- If sexually active using an effective method of contraception until at least 4 months after the last vaccination.
- Willing to forgo donating blood during the study.
Exclusion Criteria:
- Any relevant abnormality on history or examination including history of immunodeficiency or autoimmune disease, or use of systemic corticosteroids, immunosuppressive, antiviral, anticancer or other medication that, in the opinion of the Principal Investigator or designee, is clinically significant, within the previous 6 months. (Note: use of inhaled steroids for asthma or use of topical steroids for localized skin conditions will not exclude a volunteer from participation.)
- Any clinically significant acute or chronic medical condition that is considered progressive or, in the opinion of the Principal Investigator or designee, would make the volunteer unsuitable for the study.
Any of the following abnormal laboratory parameters (1 abnormal test may be repeated once if thought to be due to a temporary condition):
Haematology
- Haemoglobin < 9.0 g/dl for women and <11.0 g/dl for men
- Absolute Neutrophil Count (ANC) ≤ 1000 /mm3 (≤ 1 x 109 /l)
- Absolute Lymphocyte Count (ALC) ≤ 600 /mm3 (≤0.6 x 109 /l)
- Platelets ≤100,000 /mm3, ≥ 550,000 /mm3 (≤ 100 /l, ≥ 550 /l)
Biochemistry
- Creatinine > 1.3 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) > 2.5 x ULN
- Alanine aminotransferase (ALT) > 2.5 x ULN
Urinalysis- Clinically significant abnormal dipstick confirmed by microscopy:
- Protein = 2+ or more
- Blood = 2+ or more (for women: before or after menses)
- Confirmed HIV-1 or HIV-2 infection.
- If female, pregnant or planning a pregnancy any time from enrolment to 4 months after the last vaccination; or lactating.
- Receipt of live attenuated vaccine within the previous 60 days or planned receipt at any time until 60 days after vaccination with Investigational Medicinal Product (IMP) or receipt of other vaccine, including influenza vaccine, within the previous 14 days or planned receipt at any time until 14 days after vaccination with the IMP.
- Receipt of blood transfusion or blood products within the previous 6 months.
- Participation in another clinical trial of an IMP currently or within the previous 3 months or expected participation during this study.
- Receipt of any investigational HIV-1 vaccine within the last 6 years.
- History of severe or very severe local or systemic reactogenicity events after vaccination, or history of severe or very severe allergic reactions.
- Confirmed diagnosis of acute or chronic hepatitis B virus infection (spontaneous clearance leading to natural immunity, indicated by antibodies to core + antigens, is not an exclusion criterion); confirmed diagnosis of hepatitis C virus infection; untreated syphilis.
- Smallpox vaccination within the previous 3 years.
- Major psychiatric illness in the previous 3 years.
- History of allergy or hypersensitivity to latex, chronic skin problems such as eczema or psoriasis, or skin and subcutaneous tissue thickness > 40 mm as assessed by skin pinch test in either deltoid region.
- Presence of an implantable device
- Current use of any electronic stimulation device. Therapeutic or traumatic metal implant in either deltoid region.
- History of, or known active cardiac disease or a heart condition under the care of a doctor. Note: Slight physiological variation of normal resting heart rate (60 - 100 beats/minute) with respiration is NOT excluded.
- History of syncope or fainting episode within 1 year of study entry.
- Seizure disorder or any history of prior seizure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A - AM
Ad35-GRIN 5 x 10^10 vp IM at week 0, MVA.HIVconsv 2 x 10^8 pfu IM at week 8.
|
intramuscular administration of Ad35-GRIN 5 x 10^10 vp or saline placebo
IM administration of MVA.HIVconsv 2 x 10^8 pfu or saline placebo
|
Experimental: B - DDDAM
pSG2.HIVconsv DNA 4 mg or saline placebo at weeks 0, 4 and 8. Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20.
|
intramuscular administration of Ad35-GRIN 5 x 10^10 vp or saline placebo
IM administration of MVA.HIVconsv 2 x 10^8 pfu or saline placebo
IM administration of pSG2.HIVconsv DNA 4 mg or saline placebo
|
Experimental: C - DeDeDeAM
Electroporated pSG2.HIVconsv 4 mg or electroporated saline placebo at weeks 0, 4 and 8. Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20. |
intramuscular administration of Ad35-GRIN 5 x 10^10 vp or saline placebo
IM administration of MVA.HIVconsv 2 x 10^8 pfu or saline placebo
IM administration of electroporated pSG2.HIVconsv 4mg or saline placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaccine Safety
Time Frame: 44 weeks
|
Proportion of volunteers who develop a grade 3 or 4 local reaction.
Proportion of volunteers who develop a grade 3 or 4 systemic reaction
|
44 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaccine immunogenicity
Time Frame: 44 weeks
|
T cell responses will be determined initially by interferon-gamma enzyme-linked immunospot assay
|
44 weeks
|
Vaccine Safety
Time Frame: 44 weeks
|
A descriptive summary of grade 3 of 4 local and systemic events including laboratory abnormalities. A descriptive summary of serious adverse events, including laboratory abnormalities |
44 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Walter Jaoko, University of Nairobi
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AIDS
-
GlaxoSmithKlineCompletedAIDS | AIDS VaccinesBelgium
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
Cell Energy Life Sciences Group Co. LTDBeijing YouAn Hospital; Beijing 302 Hospital; Shenzhen Third People's Hospital; Fifth Hospital of Shijiazhuang CityRecruiting
-
ViiV HealthcarePfizerCompleted
-
University of ArizonaRecruitingHearing AidsUnited States
-
NorthShore University HealthSystemCompletedCognitive AidsUnited States
-
Sodra Alvsborgs HospitalCompleted
-
Sodra Alvsborgs HospitalCompleted
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLCCompletedAIDS-related Peripheral/Systemic Lymphoma | AIDS-related Diffuse Large Cell Lymphoma | AIDS-related Diffuse Mixed Cell Lymphoma | AIDS-related Diffuse Small Cleaved Cell Lymphoma | AIDS-related Immunoblastic Large Cell Lymphoma | AIDS-related Lymphoblastic Lymphoma | AIDS-related Small Noncleaved... and other conditionsZimbabwe, Kenya
-
Beijing 302 HospitalShanghai Public Health Clinical Center; The 6th people's Hospital of Xinjiang... and other collaboratorsRecruiting
Clinical Trials on Ad35-GRIN
-
International AIDS Vaccine InitiativeUniversity of RochesterCompletedHIV Infections | HIVUnited States
-
International AIDS Vaccine InitiativeCompleted
-
International AIDS Vaccine InitiativeAuro Vaccines LLC; Ichor Medical Systems IncorporatedCompletedHIV InfectionsRwanda, Uganda, Kenya
-
KDH Research & CommunicationCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
Crucell Holland BVCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
University of OxfordCrucell Holland BV; University of Birmingham; Emergent BioSolutions; AerasCompleted
-
Crucell Holland BVCompletedRespiratory Tract Infections | Respiratory Syncytial VirusesUnited States
-
International AIDS Vaccine InitiativeNational Institute of Allergy and Infectious Diseases (NIAID); Beth Israel... and other collaboratorsCompletedHIV InfectionsUnited States, Kenya, Rwanda, South Africa